Sirona Biochem Inducer Produces More Protein than Commercial Leader in Study
News Mar 13, 2012
Sirona Biochem Corp. has announced results of a study with its biological inducer in the expression of a difficult to produce recombinant protein.
In the study, Sirona Biochem’s inducer SBM-TFC-358 produced more protein than IPTG, a leading commercially available inducer, and was able to maintain induction over a longer period.
SBM-TFC-358 induced the synthesis of a recalcitrant protein of 13.6 kDa, known to be poorly expressed in Escherichia coli. The study was conducted by protein engineering company PX’ Therapeutics.
In the study, SBM-TFC-358 induced more protein expression than IPTG at the same concentration of 0.1 mM.
The kinetic study of induction at 37°C showed that total production (i.e. soluble and insoluble fraction) with SBM-TFC-358 was 1.7 times and 2.9 times that of IPTG at 24 and 56 hours, respectively.
“These independent results demonstrate our compound IPGMim®, when compared to IPTG, produced superior yield of a difficult to express protein - one requiring a long induction period” said Sean Cunliffe, Chief Business Officer of Sirona Biochem.
“We are excited about working with potential customers to further characterize the benefits of IPGMim® over IPTG and advance the commercialization of Sirona Biochem’s first product” added Mr. Cunliffe.
Inducers are carbohydrates which trigger recombinant protein production, which can be used in research and the manufacturing of insulin and other drugs.
The quality of the inducer is key to the production process and can affect the quality and yield of the protein. Current inducers, because they are carbohydrates, are metabolically unstable, and require special handling conditions.
Animal venoms are the subject of study at research center based at the Butantan Institute in São Paulo. But in this case, the idea is not to find antidotes, but rather to use the properties of the venoms themselves to identify molecular targets of diseases and, armed with that knowledge, develop new compounds that can be used as medicines.